Numinus Aligns Business Initiatives to Prepare for Future Approval of MDMA-Assisted Therapy Post published:May 25, 2023 Post category:Press Release
Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder Post published:May 22, 2023 Post category:Press Release
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification Post published:May 19, 2023 Post category:Press Release
Terran Biosciences discovers what may be the first new salts, co-crystals, and polymorphs of psilocybin in history, publishes PCT patent application, and files psilocybin Drug Master File (DMF) with FDA Post published:May 19, 2023 Post category:Press Release
FILAMENT HEALTH ANNOUNCES FIRST EVER NAGOYA PROTOCOL-COMPLIANT SHIPMENT OF IBOGA FROM GABON Post published:May 17, 2023 Post category:Press Release
Optimi Health Completes Harvest Of Psilocybe Cubensis For Delivery To The Australian Medical Market Post published:May 17, 2023 Post category:Press Release
Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity Post published:May 17, 2023 Post category:Press Release
FILAMENT HEALTH ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Post published:May 13, 2023 Post category:Press Release
Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder Post published:May 12, 2023 Post category:Press Release
Terran Biosciences announces publication of four PCT patent applications covering breakthroughs in novel empathogens, including improved versions of methylone, ethylone, MDEA, MDAI, and MBDB Post published:May 11, 2023 Post category:Press Release